Literature DB >> 12878500

Molecular mechanisms of itraconazole resistance in Candida dubliniensis.

Emmanuelle Pinjon1, Gary P Moran, Colin J Jackson, Steven L Kelly, Dominique Sanglard, David C Coleman, Derek J Sullivan.   

Abstract

It has previously been shown that overexpression of the CdMDR1 gene is a major contributor to resistance in fluconazole-resistant isolates of Candida dubliniensis. However, since CdMdr1p does not mediate transport of other azole drugs such as itraconazole, we investigated the molecular mechanisms of stable resistance to itraconazole obtained in three strains of C. dubliniensis (two with nonfunctional CdCDR1 genes and one with functional CdCDR1 genes) by serial exposure to this antifungal agent in vitro. Seven derivatives that were able to grow on agar medium containing 64 micro g of itraconazole per ml were selected for detailed analysis. These derivatives were resistant to itraconazole, fluconazole, and ketoconazole but were not cross resistant to inhibitors. CdMDR1 expression was unchanged in the seven resistant derivatives and their parental isolates; however, all seven derivatives exhibited increased levels of CdERG11 expression, and six of the seven derivatives exhibited increased levels of CdCDR1 expression compared to the levels of expression by their respective parental isolates. Except for one derivative, the level of rhodamine 6G efflux was decreased in the itraconazole-resistant derivatives compared to the level of efflux in their parental isolates, suggesting altered membrane properties in these derivatives. Analysis of their membrane sterol contents was consistent with a defective sterol C5,6-desaturase enzyme (CdErg3p), which was confirmed by the identification of mutations in the alleles (CdERG3) encoding this enzyme and their lack of functional complementation in a Saccharomyces cerevisiae erg3 mutant. The results of this study show that the loss of function of CdErg3p was the primary mechanism of in vitro-generated itraconazole resistance in six of the seven the C. dubliniensis derivatives. However, the mechanism(s) of itraconazole resistance in the remaining seventh derivative has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878500      PMCID: PMC166077          DOI: 10.1128/AAC.47.8.2424-2437.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei.

Authors:  K Venkateswarlu; D W Denning; S L Kelly
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

3.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.

Authors:  G P Moran; D J Sullivan; M C Henman; C E McCreary; B J Harrington; D B Shanley; D C Coleman
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.

Authors:  W R Kirkpatrick; S G Revankar; R K Mcatee; J L Lopez-Ribot; A W Fothergill; D I McCarthy; S E Sanche; R A Cantu; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Authors:  F C Odds; L Van Nuffel; G Dams
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

7.  Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Authors:  D Sanglard; F Ischer; L Koymans; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

8.  Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

Authors:  K A Marr; C N Lyons; T R Rustad; R A Bowden; T C White; T Rustad
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

9.  Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata.

Authors:  H Miyazaki; Y Miyazaki; A Geber; T Parkinson; C Hitchcock; D J Falconer; D J Ward; K Marsden; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

10.  Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis.

Authors:  G P Moran; D Sanglard; S M Donnelly; D B Shanley; D J Sullivan; D C Coleman
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  15 in total

1.  Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility.

Authors:  Laura Alcazar-Fuoli; Emilia Mellado; Guillermo Garcia-Effron; Maria J Buitrago; Jordi F Lopez; Joan O Grimalt; J Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

3.  Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.

Authors:  Emmanuelle Pinjon; Colin J Jackson; Steven L Kelly; Dominique Sanglard; Gary Moran; David C Coleman; Derek J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Longitudinal genotyping of Candida dubliniensis isolates reveals strain maintenance, microevolution, and the emergence of itraconazole resistance.

Authors:  M Fleischhacker; J Pasligh; G Moran; M Ruhnke
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

5.  Loss of C-5 Sterol Desaturase Activity in Candida albicans: Azole Resistance or Merely Trailing Growth?

Authors:  Arturo Luna-Tapia; Arielle Butts; Glen E Palmer
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes.

Authors:  Sarah MacPherson; Bassel Akache; Sandra Weber; Xavier De Deken; Martine Raymond; Bernard Turcotte
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  Evaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses.

Authors:  Whitney M Holden; Alexander R Ebert; Peter F Canning; Louise A Rollins-Smith
Journal:  Appl Environ Microbiol       Date:  2014-04-25       Impact factor: 4.792

8.  Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

Authors:  Donna M MacCallum; Alix Coste; Françoise Ischer; Mette D Jacobsen; Frank C Odds; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.

Authors:  A Forastiero; A C Mesa-Arango; A Alastruey-Izquierdo; L Alcazar-Fuoli; L Bernal-Martinez; T Pelaez; J F Lopez; J O Grimalt; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

10.  Upregulation of the ERG11 gene in Candida krusei by azoles.

Authors:  M Tavakoli; F Zaini; M Kordbacheh; M Safara; R Raoofian; M Heidari
Journal:  Daru       Date:  2010       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.